BioSpace presented the NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.

The IQVIA Institute for Human Data Science found in its latest report – Global Oncology Trends 2019: Therapeutics, Clinical Development and Health System Implications – that in 2018 a record-setting 15 new active substance oncology treatments with 17 indications, including one tissue-agnostic therapy, launched in the U.S.

Germany-based Evotec SE followed up a string of collaborations with pharma companies with the $90 million acquisition of Bill & Melinda Gates Foundation-backed Just Biotherapeutics Inc.

Lilly inked a deal with Eddingpharm for the rights to two legacy antibiotic medicines and a manufacturing facility in Suzhou, China.

Gilead Sciences and its cell therapy subsidiary Kite Pharma agreed to acquire Cell Design Labs.

Global biotherapeutics leader CSL Behring announced that Japan’s Ministry of Health, Labor and Welfare approved Afstyla [lonoctocog alfa] for hemophilia A.

ImMAGE Biotherapeutics announced the company is shutting its doors and discontinuing operations.

Pfizer plans to hire about 80 new staffers when the company completes construction of its new research-and-development campus in Chesterfield, Missouri.

Cambridge, Mass.-based Momenta Pharmaceuticals and Australia-based CSL Limited announced they had signed a research collaboration and global licensing deal.

Healthcare spending in the United States will likely grow by an average 5.8 percent per year over the next decade according to updated projections from the federal government.